Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion ‐dependent thalassaemia and HCV genotype 1 or 4 infection

ConclusionsIn conclusion, SOF/LDV for 12 weeks provides simple, highly effective and safe Peg‐IFN/RBV‐free treatment for HCV GT1/4 thalassaemia patients. EUDRACT number 2015‐002401‐1.

Source: Alimentary Pharmacology and Therapeutics - June 29, 2017 Category: Drugs & Pharmacology Authors: A. Mangia, R. Sarli, R. Gamberini, A. Piga, G. Cenderello, V. Piazzolla, R. Santoro, V. Caruso, A. Quarta, R. Ganga, M. Copetti, G. Forni Tags: RANDOMISED CLINICAL TRIAL Source Type: research